Xuanzhu Biopharmaceutical reports BRIGHT-2 Phase 3 results for Bireociclib plus fulvestrant in HR+/HER2- breast cancer

Reuters03-24

Xuanzhu Biopharmaceutical reports BRIGHT-2 Phase 3 results for Bireociclib plus fulvestrant in HR+/HER2- breast cancer

Xuanzhu reported final Phase 3 BRIGHT-2 results for its breast cancer product bireociclib in combination with fulvestrant, with the analysis published in JAMA Oncology.
The company said median progression-free survival was 14.7 months versus 7.3 months for placebo plus fulvestrant, with a 46% reduction in risk of progression or death (HR=0.54).
In patients with measurable disease, the objective response rate was 50.3% versus 16.7% for the control group.
Xuanzhu said bireociclib has been approved in China for use with fulvestrant in HR+/HER2- advanced or metastatic breast cancer after progression on prior endocrine therapy, positioning it for broader clinical adoption.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xuanzhu Biopharmaceutical Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260324-12065003), on March 24, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2621069888?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-24 19:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2621069888","market":"fut","top_or_hot":-1,"title":"Xuanzhu Biopharmaceutical reports BRIGHT-2 Phase 3 results for Bireociclib plus fulvestrant in HR+/HER2- breast cancer","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Xuanzhu Biopharmaceutical reports BRIGHT-2 Phase 3 results for Bireociclib plus fulvestrant in HR+/HER2- breast cancer\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Xuanzhu reported final Phase 3 BRIGHT-2 results for its breast cancer product bireociclib in combination with fulvestrant, with the analysis published in JAMA Oncology.\n        </li>\n<li>\n          The company said median progression-free survival was 14.7 months versus 7.3 months for placebo plus fulvestrant, with a 46% reduction in risk of progression or death (HR=0.54).\n        </li>\n<li>\n          In patients with measurable disease, the objective response rate was 50.3% versus 16.7% for the control group.\n        </li>\n<li>\n          Xuanzhu said bireociclib has been approved in China for use with fulvestrant in HR+/HER2- advanced or metastatic breast cancer after progression on prior endocrine therapy, positioning it for broader clinical adoption.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xuanzhu Biopharmaceutical Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260324-12065003), on March 24, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Xuanzhu Biopharmaceutical reports BRIGHT-2 Phase 3 results for Bireociclib plus fulvestrant in HR+/HER2- breast cancer</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nXuanzhu Biopharmaceutical reports BRIGHT-2 Phase 3 results for Bireociclib plus fulvestrant in HR+/HER2- breast cancer\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-24 19:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Xuanzhu Biopharmaceutical reports BRIGHT-2 Phase 3 results for Bireociclib plus fulvestrant in HR+/HER2- breast cancer\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Xuanzhu reported final Phase 3 BRIGHT-2 results for its breast cancer product bireociclib in combination with fulvestrant, with the analysis published in JAMA Oncology.\n        </li>\n<li>\n          The company said median progression-free survival was 14.7 months versus 7.3 months for placebo plus fulvestrant, with a 46% reduction in risk of progression or death (HR=0.54).\n        </li>\n<li>\n          In patients with measurable disease, the objective response rate was 50.3% versus 16.7% for the control group.\n        </li>\n<li>\n          Xuanzhu said bireociclib has been approved in China for use with fulvestrant in HR+/HER2- advanced or metastatic breast cancer after progression on prior endocrine therapy, positioning it for broader clinical adoption.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xuanzhu Biopharmaceutical Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260324-12065003), on March 24, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1515","symbol_name":"抗疫概念","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nNDL20tgp6:1","article_id":"2621069888","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2621069888","pubTimestamp":1774350387,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Xuanzhu reported final Phase 3 BRIGHT-2 results for its breast cancer product bireociclib in combination with fulvestrant, with the analysis published in JAMA Oncology.The company said median progression-free survival was 14.7 months versus 7.3 months for placebo plus fulvestrant, with a 46% reduction in risk of progression or death .In patients with measurable disease, the objective response rate was 50.3% versus 16.7% for the control group.Xuanzhu said bireociclib has been approved in China for use with fulvestrant in HR+/HER2- advanced or metastatic breast cancer after progression on prior endocrine therapy, positioning it for broader clinical adoption.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xuanzhu Biopharmaceutical Co. Ltd","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1515":"抗疫概念","BK1191":"制药","00460":"四环医药","BK1593":"医美概念股","BK1600":"工业大麻","02575":"轩竹生物-B"},"translate_title":"轩竹生物制药报告Bireociclib联合氟维司群治疗HR+/HER2-乳腺癌的BRIGHT-2 3期结果","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02575":0.9,"00460":0.9},"content_text":"Xuanzhu Biopharmaceutical reports BRIGHT-2 Phase 3 results for Bireociclib plus fulvestrant in HR+/HER2- breast cancer\n    \n\n\n          Xuanzhu reported final Phase 3 BRIGHT-2 results for its breast cancer product bireociclib in combination with fulvestrant, with the analysis published in JAMA Oncology.\n        \n\n          The company said median progression-free survival was 14.7 months versus 7.3 months for placebo plus fulvestrant, with a 46% reduction in risk of progression or death (HR=0.54).\n        \n\n          In patients with measurable disease, the objective response rate was 50.3% versus 16.7% for the control group.\n        \n\n          Xuanzhu said bireociclib has been approved in China for use with fulvestrant in HR+/HER2- advanced or metastatic breast cancer after progression on prior endocrine therapy, positioning it for broader clinical adoption.\n        \n\n\n\n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xuanzhu Biopharmaceutical Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260324-12065003), on March 24, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2621069888","isCrawlerRequest":true}